IL-18BP Protein (Primary Amine Labeling), Cynomolgus, Recombinant (His), Biotinylated

Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer,components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice. IL-18BP Protein (Primary Amine Labeling), Cynomolgus, Recombinant (His), Biotinylated is expressed in HEK293 mammalian cells with C-His tag. The predicted molecular weight is 21.14 kDa and the accession number is A0A2K5UDJ4.

规格	价格/CNY		数量
100 μg	￥ 5,180	5日内发货
500 μg	￥ 20,700	5日内发货
1 mg	￥ 34,600	5日内发货

规格

价格/CNY

货期

数量

100 μg

￥ 5,180

5日内发货

500 μg

￥ 20,700

5日内发货

1 mg

￥ 34,600

5日内发货

生物活性

Biotinylated Cynomolgus IL-18BP, His tag captured on CM5 Chip via anti-his antibody can bind Human IL-18, No Tag with an affinity constant of 1.67 nM as determined in SPR assay.

产品描述

种属	Cynomolgus
表达系统	HEK293 Cells
标签	C-His
蛋白编号	A0A2K5UDJ4
别名	Igifbp, Interleukin-18-binding protein, IL-18BP
蛋白构建	Thr28-Pro207
蛋白纯度	> 95% as determined by Tris-Bis PAGE; > 90% as determined by HPLC
分子量	21.14 kDa (predicted). Due to glycosylation, the protein migrates to 50-65 kDa based on Tris-Bis PAGE result.

内毒素	< 1 EU/μg by the LAL method.
缓冲液	Supplied as 0.22 μm filtered solution in PBS (pH 7.4).
存储	It is recommended to store the product under sterile conditions at -70℃ or lower. Samples are stable for up to 12 months at -80℃. Please avoid multiple freeze-thaw cycles and store products in aliquots.
运输方式	In general, Lyophilized powders are shipping with blue ice. Solutions are shipping with dry ice.
研究背景	Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer,components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice.